• Welcome to Gu Group

    The Gu Group (iMedication Lab) at Zhejiang University aims to develop transformative drug delivery systems, especially for treating cancer and diabetes, as well as enhancing people's quality of life.

    READ MORE
  • Therapeutic Gel

    In Situ Formed Reactive Oxygen Species-Responsive Scaffold with Gemcitabine and Checkpoint Inhibitor for Combination Therapy

    READ MORE
  • Smart Insulin Patch

    Microneedle-Array Patches Loaded with Hypoxia-Sensitive Vesicles Provide Fast Glucose-Responsive Insulin Delivery

    READ MORE
Smart Insulin Patch

Smart Insulin Patch

A painless microneedle array patch for glucose-responsive smart insulin delivery, enhancing health and qualify of life of people with diabetes. This is the first prototype for the closed-loop transdermal drug delivery. (PNAS, 2015; Nature Biomedical Engineering, 2020)

READ MORE
Smart Insulin Patch

Immunotherapeutic Gel

In situ formed sprayable/ injectable bioresponsive gels with immunotherapeutics, e.g., immune checkpoint inhibitor for local delivery, associated with primary tumor and post-surgical treatment. (Science Translational Medicine, 2018; Nature Nanotechnology, 2019)

READ MORE
Smart Insulin Patch

Artificial Beta Cells (AβCs)

Construction of synthetic artificial beta cells (AβCs) with a 'vesicles-in-vesicle' superstructure equipped with a membrane-fusion machinery for glucose-responsive insulin delivery. (Nature Chemical Biology, 2017)

READ MORE
Smart Insulin Patch

Platelets for Immunotherapy

Platelets loaded with immune checkpoint antibodies for surgical site targeting and in situ activation for inhibiting tumor recurrence and metastasis. This strategy can also be used for inhibiting recurrence of leukemia. (Nature Biomedical Engineering, 2017; Nature Biomedical Engineering, 2018)

READ MORE

About Gu Research Group

Our iMedication Lab is interested in integrating biomaterials design, biomacromolecular engineering, and micro/nano-fabrication towards new drug delivery strategies, which apply stimuli-responsive systems for delivering and/or releasing therapeutics in dose-, spatial- and temporal-controlled manners. Our current focus is to leverage physiology for bioresponsive drug delivery through cellular carriers or biomimetic synthetic vehicles.

read more

Latest news

Jun., 2020 - Gu Lab is moving to Zhejiang University. Welcome to Hangzhou!

Feb., 2020 - Smart Insulin Patch 2.0" was published in Nature Biomedical Engineering.

Mar., 2019 - Dr. Gu was elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE).

Jan., 2019 - Qian Chen's sprayable immunotherapeutic gel was published in Nature Nanotechnology.

read more
Latest Cover Paper/Publications

Spray-on gel for post-surgery cancer immunotherapy

View all Publications

In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment

150. Qian Chen, Chao Wang, Xudong Zhang, Guojun Chen, Quanyin Hu, Hongjun Li, Jinqiang Wang, Di Wen, Yuqi Zhang, Yifei Lu, Guang Yang, Chen Jiang, Jun Wang, Gianpietro Dotti and Zhen Gu*

Glucose Transporter Inhibitor-Conjugated Insulin Mitigates Hypoglycemia

176. Jinqiang Wang, Jicheng Yu, Yuqi Zhang, Anna R.Kahkoska, Zejun Wang, Jun Fang, Julian P. Whitelegge, Song Li, John B. Buse, and Zhen Gu*

Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs

206. Jicheng Yu, Jinqiang Wang, Yuqi Zhang, Guojun Chen, Weiwei Mao, Yanqi Ye, Anna R. Kahkoska, John B. Buse, Robert Langer and Zhen Gu*